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HIV prevention has received renewed attention with the release of results from clinical trials 
dealing with the efficacy and safety of HIV pre-exposure prophylaxis (PrEP), particularly 
once daily Truvada, within the last decade. 
The results seemed to suggest that PrEP is efficacious with high levels of adherence. 
This culminated in the South African Medicines Control Council (MCC) approving use of 
Truvada as HIV PrEP in December 2015, coupled with the release of SA HIV Clinicians 
Society guidelines in February 2016. 
Several issues were found to be involved in prescribing Truvada as PrEP, including clinical 
monitoring,  adherence counselling, and potential for patient behavioural disinhibition.  
The objective of this thesis is to discuss the results of an online survey administered to South 
African doctors, on their opinions on the  use of Truvada as PreP. 
Part A deals with the survey protocol and focuses on (1)ethical issues such as approval by the 
University of Cape Town Research Ethics Committee, and obtaining consent, (2) method of 
data collection and (3) procedure of data analysis. 
Part B is a literature review expanding on the topics described in the Background section, 
including extent of problem posed by HIV, failure to develop a viable HIV vaccine, need for 
HIV PrEP, review of previous research on HIV PrEP, and the need for a study on South 
African doctors’ opinions on PrEP. 
Part C is a manuscript that shows the results of the survey, analysis of the data and a 
discussion on the possible implications. 
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PART A: PROTOCOL 
SYNOPSIS: 
Background and purpose:  
Despite the widespread availability of antiretroviral drugs and extensive research to develop 
an HIV (human immunodeficiency virus) vaccine, South Africa still has one of the highest 
HIV rates in the world. Thus, research has continued to find other HIV prevention  modalities 
These include HIV pre-exposure prophylaxis (PrEP), either taken orally or as a microbicide 
gel or ring.  
Clinical trial data suggests that HIV PrEP is efficacious, but that efficacy depends to a large 
extent on HIV PrEP client adherence. 
The evidence has however been sufficient to justify the approval of Truvada ( 
tenofovir/emtricitabine) as PrEP by the Food and Drug Administration (FDA) on 16 July 
2012 in the United States, and more recently by the Medicines Control Council in December 
2015 in South Africa (SA). Coupled with this has been the advent of SA HIV Clinicians 
Society and Centres for Disease Control (CDC) guidelines in 2012 and 2014 respectively. 
Implementation of these guidelines however require motivated clinicians who are 
knowledgeable about the indications for prescribing PrEP,;possible side effects, and 
counselling methods to ensure maximal adherence to the recommended dose of once-daily 
Truvada.. 
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This preliminary survey thus attempts to monitor whether South African clinicians, are ready 
to prescribe PrEP to patients. 
 
Objectives: 
Main objective is to ascertain how many South African based doctors, are willing to prescribe 
Truvada as HIV PrEP. 
Other objectives are to elucidate knowledge of participating providers about PrEP, barriers 
and facilitating factors to prescribing PrEP as seen by the participating providers such as 
concerns about HIV medication resistance, side effects and the belief that prescribing PrEP is 
the domain of other physicians. 
 
Methods:  
Study design:  
The study is a cross-sectional survey that will be administered online. 
Selection criteria: 
The population that will be studied are doctors who are members of the South African 
Medical Association (SAMA). 
Recruitment: 
The doctors will be approached via an email sent by SAMA to participate in the proposed 




Consent will be obtained online via a consent form that will be included within the survey. 
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Data collection and analysis: 
The online survey was created using the applicationSurvey Monkey. The participants will fill 
in the survey if they consent, and as each of them submits their responses an online database 
will be created that will record each response of the participants in a spreadsheet, which can 
then be exported to Excel. 
 
Exploration of the data will first be performed using means, medians, standard deviations 
and/or interquartile ranges on single variables that may be predictor variables associated with 
willingness of the provider to prescribe PrEP. 
 
Logistic regression analysis will then be performed first using univariable analysis and then 
using multivariable analysis through attempting to build a model using forward selection  and 
selecting predictor variables for inclusion by likelihood ratio testing.  
All statistical analyses will be performed using STATA version 12 statistical software, and 
where applicable graphical representation of data will be performed using Excel 2010. 
Ethical issues:  
Potential risks to participants:  
There are no anticipated risks to the participants. 
Protection of confidential information:  
No identifiable information will be entered into the online questionnaire or database at any 
point.. Access to these will be limited to the investigators, the Faculty of Health sciences 
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Post-trial measures:  
An Ipad can be won by 1 doctor as part of a competition. Also  additional literature in the 
form of a 9 page summary of the current guidelines will be offered to each participant. Each 
participant will be able to request the information package or to be part of the competition 
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PROBLEM STATEMENT 
Human Immunodeficiency Virus (HIV) has remained a significant cause of morbidity and 
mortality despite decades of research. Research has focussed on treatment and prevention 
methods such as condom use, and more recently Truvada as HIV pre-exposure 
prophylaxis.(PrEP). 
Use of Truvada as HIV pre-exposure prophylaxis requires motivated clinicians aware of the 
many associated clinical issues such as monitoring for side effects and counselling to 
optimize adherence. 
The protocol described below thus involves administration of an online survey testing 
knowledge and opinions of South African doctors on prescription of Truvada as PrEP.   
RESEARCH JUSTIFICATION: 
Need for HIV pre-exposure prophylaxis 
Despite our modern advances, HIV remains a challenging problem which has eluded all 
attempts to find a cure or suitable vaccine. 
 
Evidence for Truvada as HIV PrEP 
As a result, a number of other approaches, notably use of  Truvada as pre-exposure 
prophylaxis (PrEP) have been attempted to prevent HIV in people at risk. 
 
Recent evidence have suggested that this approach is efficacious. Examples of studies that 
have demonstrated this include  iPrEx study involving 2499 men who have sex with men that 
showed a reduction in HIV of 44% compared to placebo1, the Partners PrEP study involving 
4747 heterosexual serodiscordant couples showed a 67% reduction in HIV incidence  using 
oral tenofovir, and a 75% reduction in HIV incidence using oral Truvada, relative to  
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placebo2 , The TDF2 study involving 1200 men and women in Botswana  taking once-daily 
oral Truvada showed an efficacy of 62%.3  and the Bangkok Tenofovir study involving 2413 
men and women who injected drugs in Thailand showed a 66% efficacy incidence compared 
using once-daily oral Truvada as HIV PrEP. 4 
As a result of these and other studies the Medicines Control Council (MCC) in South Africa 
opted to approve the use of Truvada as PrEP in December 2015.6  This coincided with the 
release in February 2016 of  the “Southern African guidelines on the safe use of pre-exposure 
prophylaxis in persons at risk of acquiring HIV infection”.10 
 
Clinical concerns associated with HIV PrEP 
The guidelines highlight several clinical concerns that clinicians prescribing Truvada as PrEP 
need to be aware of including monitoring of renal function, bone mineral density, and the 
importance of monitoring of and ensuring good adherence. Thus motivated and informed 
clinicians will be crucial to ensuring success of the Truvada PrEP regimen for patients. 
 
Previous research on Truvada as HIV PrEP 
To date, there has not been many studies that assessed knowledge and opinions of doctors on 
prescribing PrEP, and most have been performed in developed countries notably 2 studies 
involving a quantitative survey of physicians in Canada7 and a qualitative survey of 
American physicians9.  
The studies mentioned in addition to some others have also added some issues that are 
pertinent particularly from the point of view of the clinicians that enrolled, in addition to 
issues mentioned in the South African HIV Clinicians guidelines10 and CDC guidelines.5 
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These studies show that under 50% of American physicians are willing to prescribe PrEP. 7,8
The studies, both quantitative and qualitative, also show several perceived barriers to PrEP 
implementation including logistical concerns associated with monitoring, a feeling that more 
research still needs to be done to show efficacy, perceived medical risks such as increased 
HIV resistance if patients become HIV infected, and concerns about patient lack of adherence 
and possible risk compensation. 7,8,9 
To elucidate further on these concerns and barriers expressed by clinicians in previous 
surveys, the following factors were noted to reduce potential provider willingness to 
prescribe PrEP: 
(1) Lack of knowledge of oral PrEP. Surprisingly, 16.5% of providers in a Canadian
survey were not familiar with PrEP 7 and 57.5% of healthcare providers in a physician
survey conducted in Lima, Peru were aware of PrEP 8
(2) Belief that the existing evidence from clinical trials was insufficient to justify
widespread prescription 7
(3) “Lack of clarity regarding which patient populations were appropriate for PrEP” 7
(4) belief by providers that adherence to PrEP would be substantially less in real-world as
opposed to clinical trial settings, thus significantly compromising its effectiveness. A
concern was also expressed that this would particularly apply to high-risk patients.
9 
(5) concern about time constraints in busy general practices making adherence and risk
reduction counselling suboptimal 9 
(6) concern about patients not accurately disclosing their sexual behaviour patterns, thus
causing providers to potentially miss indications to prescribe PrEP in some cases 9
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(7) concerns about the high costs of the medication, limiting patients’ ability to access 
Truvada as PrEP 8,9 
(8) concerns about medication related toxicities, and the belief that patients on PrEP 
would have a far lower tolerance for these given the fact that they are healthy and 
HIV negative 9 
(9) concerns about HIV medication resistance 8,9 
(10) concerns about patient risk compensation ie engaging in more risky behaviour after 
starting PrEP 9 
(11) Inexperience in dealing with the demands created by prescribing PrEP 7 
(12) the so-called “Purview Paradox” where HIV specialists tended to believe that PrEP 
should be prescribed by general practitioners as most patients seen by HIV 
specialists are already HIV positive and do not need PrEP, while in contrast the 
general practitioners felt that the HIV specialists were more equipped to deal with 
the monitoring and counselling demands engendered by prescribing PrEP 9 
(13) Perception by clinicians that potentially eligible clients were not interested in 
starting PrEP 7,9 
 
The studies, however, also pointed out several factors that the participating physicians 
identified would potentially facilitate their willingness to prescribe PrEP. 
These factors include: 
(1) belief in the efficacy of PrEP based on previous clinical trial data would create a sense 
of duty in physicians to prescribe it, despite the problems mentioned above 7,8,9 
(2) patient motivation, more specifically, patients who were empowered enough to ask 
physicians about PrEP 9 
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(3) presence of normative guidelines such as those eventually published by the CDC and 
knowledge that respected peers have already started prescribing PrEP 8,9 
 
All the research studying physician readiness to prescribe PrEP seems to have been 
conducted overseas. As South Africa has the highest HIV rate in the world, and PrEP is a 
powerful tool for prevention of HIV, cooperation of and knowledge of South African doctors 
or other prescribers is vital to ensure that implementation of existing PrEP guidelines is 
successful.  
 
There is thus a need for a survey that measures the willingness and attitudes of South African 
doctors and other types of providers to prescribe PrEP. 
 
This cross-sectional online survey thus attempts to perform a preliminary analysis to ascertain  






1. The primary objective is to establish the willingness of South African  based doctors 
to prescribe HIV PrEP. The method by which this will be done will be described 
below. 
2. Secondary objectives include: 
 To establish whether provider willingness to prescribe PrEP is associated with 
the proportion of MSM patients in the doctor’s practice 
Llewellyn Fleurs (FLRLLE001) 
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 To establish whether provider willingness to prescribe PrEP is associated with 
the reported percentage of HIV negative patients at high risk of HIV 
acquisition in the doctor’s practice 
 To establish whether provider willingness to prescribe PrEP is associated with 
the doctor’s practice serving a high percentage of HIV positive patients 
 To establish whether provider willingness to prescribe PrEP is associated with 
providers self-identifying as HIV experts 
 To establish whether being asked about PrEP by one or more patients 
influences willingness to prescribe PrEP 
 To establish whether provider willingness to prescribe PrEP is associated with 
doctor’s opinion on what constitutes an acceptable efficacy 
 To assess whether the “purview” paradox, namely that doctors believe 
prescribing PrEP is the responsibility of other physicians, is present in doctors 
based in South Africa. 
3. Exploratory objectives may include but are not limited to: 
 To assess which medium of provider education leads to greater awareness or 
knowledge of HIV PrEP. 
 To assess whether years of experience of a doctor influences willingness to 
prescribe PrEP. 
 To assess whether the sex of a provider influences willingness to prescribe 
HIV PrEP. 
 To assess how many providers agree with the MCC decision to register 
Truvada as HIV PrEP as well as for HIV treatment. 
 To assess whether concerns about the safety of HIV PrEP influences provider 
willingness to prescribe it. 
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 To assess whether concerns about the creation of HIV drug resistance on the 
part of providers will influence willingness to prescribe PrEP. 
 To assess whether concerns about patient adherence to Truvada as PrEP will 
influence doctors’ willingness to prescribe PrEP. 
 To assess whether other provider demographic factors such as the type of 
practice influence willingness to prescribe PrEP. 
 To assess whether other barriers or facilitating factors identified by providers 





(1) The primary hypothesis is that at least 40% of  South African doctors will be willing 
to prescribe PrEP. This estimate is based on the results from the previous studies 
mentioned under “Research Justification” showing willingness to prescribe at over 
40% but under 50%.7,8,9 As South Africa has a much higher HIV prevalence and 
incidence than the US, it is thus hypothesized that doctors in  South Africa will be at 
least equally willing to prescribe PrEP. 
(2) Secondary hypotheses are as follows: 
 Doctors who identify themselves as running practices that serve a substantial 
population of gay, bisexual, and other men who have sex with men as asked in 
question 17 will be more willing to prescribe PrEP.  
 Doctors who serve a high proportion of HIV negative patients at high risk of 
HIV acquisition will be more willing to prescribe PrEP.  
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 Doctors who serve a high proportion of HIV positive patients will be more 
willing to prescribe PrEP.  
 Doctors who identify themselves as HIV experts  as asked in question 13, will 
be more likely to prescribe PrEP. 
 Doctors who self report at least 1 patient asking them about HIV PrEP as 
asked in question 22 will be more willing to prescribe PrEP. 
 Doctors who believe that at least 60% reduction in HIV incidence constitutes 
acceptable efficacy, will be less willing to prescribe PrEP.  
 It is hypothesized that a “purview paradox” may well be present in the sample 
of South African doctors, as will be tested by showing that at least 40% of 
self-identified HIV specialists believe that prescribing PrEP is the 
responsibility of general practitioners or other specialists, and vice-versa. 




The proposed research study will be a cross-sectional survey, conducted online. 
 
Selection of participants 
As this is a preliminary analysis, a sample of doctors based in South Africa  will be 
approached via an online survey. The doctors will be chosen from the South African Medical 
Association (SAMA) database. South Africa is a very diverse country, with a wide range of 
people of varying ages, racial groups, occupations and also differing risk of HIV acquisition. 
For example, there is a relatively high number of vulnerable groups such as men who have 
sex with men (MSM) and serodiscordant couples. 
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Thus doctors in South Africa will serve a large number of patients with these characteristics, 
and will thus be very likely to already be knowledgeable about PrEP and willing to prescribe 
it due to patient demand. 
Sampling procedure 
Proportional sampling will be used, by bulk emailing South African doctors who are 
members of the South African Medical Association, who form a subset of South African 
doctors who are all required to be registered with the Health Professions Council of South 
Africa (HPCSA). Each email will contain a message briefly describing the study, and a link 
to the online survey. A sample copy of the email that will be sent to each doctor is attached as 
Appendix 1. 
From previous studies (Tan and Tang papers) the response rate seems to be about 10%, 
making an adequate number of completed surveys to analyse and answer the research 
question. 
Ethical concerns 
An online consent form will be included after the title page as part of the online survey. The 
informed consent document is shown in Appendix 2. A block asking whether the study 
participant agrees to take the survey will need to be ticked before the participant can proceed 
with the rest of the survey. Failure to tick this box, that is, not giving consent will render the 
subject unable to continue. 
The informed consent document briefly describes the purpose of the study and the rationale 
for it, namely to assess whether doctors are ready and willing to implement PrEP guidelines 
and prescribe PrEP now that the MCC has registered use of Truvada as HIV PrEP in South 
Africa.  
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The informed consent document also reminds participants of the voluntary nature of the 
survey. The consent also emphasizes voluntary participation by stating that the survey allows 
you to not complete the questionnaire without submitting answers at any time before the 
“done” button is pressed. 
Explanation of procedures, that is, instructions to fill in the questionnaire are also included in 
the informed consent document. 
The informed consent document also emphasizes that confidentiality will be maintained at all 
times. The consent explains that the survey itself does not require the participant to enter any 
identifying information.  
The consent document also goes on to describe that there should be no risk associated with 
choosing to participate in the study. 
 
The consent form also describes potential benefits of choosing to participate in the survey. 
An incentive is provided in the form of being entered into a draw to win an Ipad and/or 
downloading the new South African guidelines on HIV PrEP10. (Appendix 3) In order to 
receive either of these the participant will be required to send an email to Dr Llewellyn Fleurs 
stating whether they want to enter the draw for the Ipad or will be able to download literature 
on HIV PrEP from within the survey, or both. Despite having to send an email to enter the 
draw for the Ipad, it will not be possible to link the survey responses with any email 
addresses of the participants. 
 
Data collection 
As stated above, an email containing a link to an online survey will be sent to South African 
doctors who are members of SAMA. The online survey was created by using Survey 
Llewellyn Fleurs (FLRLLE001) 
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Monkey. A copy of the online survey is shown in Appendix 4. A live copy of the survey can 
also be perused online at  https://www.surveymonkey.com/r/8KW3TNK 
The questionnaire, as per the Tan paper 7, is divided into 4 domains: 
(a) Demographic and practice based information 
(b) Doctors’ knowledge of and experience with HIV PrEP 
(c) Doctor’s opinions, beliefs and concerns about PrEP 
(d) Learning needs regarding HIV PrEP  identified by the doctors 
 
The questions dealing with the demographics and practice information for each doctor is as 
below, namely: 
Practice location, sex, type of doctor, type of practice, and whether the doctor identifies 
him/herself as an HIV specialist, the answers of which are recorded as categorical variables. 
Also, percentage of time spent in clinical activities, years of independent practise, percentage 
HIV positive patients, percentage high risk HIV negative patients, percentage MSM or 
intravenous drug users (IDUs). 
 
Questions dealing with doctor’s knowledge of HIV PrEP are as follows: 
Self-reported knowledge of HIV PrEP (on Likert scale), where the practitioner heard about 
PrEP, whether the practitioner was questioned by a patient about PrEP, and who asked the 
doctor about PrEP. 
 
Questions on doctor opinions and beliefs about HIV PrEP are administered as follows: 
A question on whether PrEP is dangerous and other statements about PrEP on a Likert scale, 
what the doctor defines as high risk, whether the doctor agrees with the Medicine Control 
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Council’s (MCC) decision to register Truvada as PrEP, who should pay for it, and who is 
responsible for prescribing it. 
Other questions testing beliefs or opinions include minimum level of efficacy clinicians are 
willing to accept, how many sexual partners equates to high risk, and how many occasions of 
unprotected sex the practitioner regards as risky. 
Self-identified gaps in knowledge on PrEP is tested for by the following: 
A question testing the reaction to statements about PrEP knowledge tested on a Likert scale, 
media needed to learn more about PrEP, barriers in prescribing PrEP (Likert scale) and 
support needed to prescribe.. 
Finally, 2 open-ended questions on what more is needed to implement the  new PrEP 
guidelines, and whether the doctor has any further thoughts to add, are given for possible 
analysis of further themes that may emerge. 
The questionnaire was pilot-tested by individuals working at the Desmond Tutu Vaccine 
Centre including 3 doctors, our laboratory project manager and data manager for consistency 
and ease of use. 
 
Data analysis and statistical methods 
Sample size required is as follows: 
From the previous studies 7,8 about 50% of doctors +- 10% were willing to prescribe PrEP. 
Using the formula n= p*(1-p)*z2/d2 where  p is the anticipated population proportion , d= 
precision required on either side of the proportion, and z = the cutoff value of the Normal 
distribution11 then the required size to estimate proportion of doctors willing to prescribe 
PrEP to +-0.1 is 97. 
Statistical analyses will be performed as described below: 
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The outcome variable is what percentage of South African based doctors will be willing to 
prescribe HIV PrEP to their patients. 
Assessing the percentage of doctors willing to prescribe HIV PrEP will be accomplished by 
tabulating the answers of each doctor to question 31, namely “Knowing what you know now, 
would you be willing to prescribe PrEP”, and calculating the percentage of doctors willing 
and unwilling to prescribe PrEP. 
Percentages of variables obtained from the question answers, for example, percentage male 
and female doctors, will be calculated using STATA 12, and the results tabulated. 
Box-and-whisker plots will be performed to graphically show any relationship between 
selected predictor variables, for example, mean minimum acceptable efficacy versus doctor 
willingness to prescribe PrEP. Significance of any differences in means noted will be tested 
for using one-way analysis of variance (ANOVA) or unpaired t-tests as appropriate. 
Formal hypothesis testing will then be performed using Chi-squared tests and the 
corresponding odds ratios for the outcome variable and each predictor variable  for the 
following: 
(1) Willingness to prescribe PreP versus self-identification as an expert in HIV care  
(2) Willingness to prescribe PreP versus percentage of HIV positive patients in the 
doctors’ practices. The percentage HIV positive patients will be dichotomized to less 
than 40% and 40% or above. 
(3) Willingness to prescribe PreP versus percentage of high risk HIV negative patients in 
the doctors’ practices. The percentage high risk HIV negative patients will be 
dichotomized to less than 40% and 40% or above. 
(4) Willingness to prescribe PreP versus percentage of males who have sex with males 
(MSM) in the doctors’ practices. The percentage of MSM  will be dichotomized to 
less than 40% and 40% or above. 
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(5) Willingness to prescribe PreP versus being asked by at least one patient about PrEP.
(6) Willingness to prescribe PreP versus doctor perception of what constitutes minimum
acceptable percentage protection against HIV.
(7) Willingness to prescribe PreP versus whether the participating doctors feel that
prescribing PrEP is their responsibility or not ( the “purview paradox”9).
Where applicable, if any cells in the 2x2 tables have values of 5 or less, Fischer’s exact 
test will be used instead of the Chi-squared test. 
A summary of this hypothesis testing will then be presented. 
Graphs plotting answers to Question 44 namely “Please rank the THREE considerations you 
believe are the MOST IMPORTANT in order from LEAST to MOST important” ie a Likert 
scale, will be plotted versus willingness to prescribe PrEP. 
The data for these graphs will be exported from STATA 12, and Excel 2010 will then be used 
to further calculate the relevant percentages and plot the resulting graphs. 
Logistic regression will then be performed to analyse associations between predictor 
variables and willingness to prescribe PrEP, and a logistic regression model will then be built 
using a forward selection strategy. Likelihood ratio tests will be performed and a Chi-squared 
p-value of 0.05 or less will be used to decide whether variables are included in the model, and
p-values of 0.1 used as an exclusion criterion.
The logistic regression model will also be used to derive change in willingness of providers 
to prescribe PrEP with each 10% increase in reported number of high risk HIV negative 
patients, each 10% increase in HIV positive patients, each 10% increase in demographic 
variables such as time spent in clinical work, teaching, public health, and administrative 
work, each 10 year increase in experience practising independently, and each 10% increase in 
what constitutes acceptable efficacy for PrEP. 
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Missing data including respondents not answering the outcome question 31 namely 
“Knowing what you know about PrEP now, would you prescribe PrEP for a patient at high 
risk of infection?” will entail an approach using complete case analysis, involving deletion of 
observations or cases with missing data.  
The exception to this will be observations for doctors who stated that they have no previous 
knowledge of PrEP in response to Question 18: “How would you describe your current 
knowledge of HIV pre-exposure prophylaxis”, who will be required to skip questions through 
to Question 30 by the survey. As long as the respondent answered the other questions and the 
outcome question their observations will not be deleted. 
 
STATA version 12 statistical software will be used for all statistical calculations, and as 
stated above, Excel 2010 where applicable. 
As the emphasis for this dissertation is mainly on quantitative research, the qualitative 
components of the questionnaire will not be analysed. This, however, may be done at a later 
stage if analysis of the qualitative component highlights new themes not identified by 
analysis of the closed questions. 
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ABBREVIATIONS AND DEFINITIONS 
 
ANOVA:           Analysis of variance 
 
Antiretrovirals: medication normally used to treat HIV, but which can also be used for pre- 
                          exposure prophylaxis 
 
CDC:                Centres for Disease Control 
Efficacy:          reduction in HIV percentage resulting from use of PrEP in the exposed group  
                        in a clinical trial, compared to those in the trial receiving placebo 
 
HIV:                Human Immunodeficiency Virus, the cause of Acquired Immune Deficiency     
                        Syndrome 
HPCSA           Health Professions Council of South Africa 
 
MCC:             Medicines Control Council of South Africa 
MSM:            males who have sex with males 
 
PrEP:              pre-exposure prophylaxis, which is the use of medication normally used to   
                       treat HIV, but in this case used to prevent HIV and taken before a person is   
                      exposed to HIV 
 
PEP:               post-exposure prophylaxis, which is use of antiretrovirals for 1 month after  
                       an event that potentially exposes a person to HIV 
Plasma:         part of blood excluding red blood cells 
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Randomization: random allocation of a study participant to a group 
Resistance:   non-susceptibility to HIV medications of the HIV virus, in individuals who 
become HIV positive while on PrEP 
SA:               South Africa 
Seroconversion: person converting from HIV negative to becoming HIV positive 
Truvada:        combination tablet  consisting of  the HIV medications tenofovir combined 
with emtricitabine 
US: United States 
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OBJECTIVES OF LITERATURE REVIEW: 
The objectives of this literature review include: 
(1) Describing the background to the proposed research question, including statistics on
the global extent of HIV, and particularly in South Africa.
(2) Explain the need for approaches to HIV prevention and treatment other than the use of
antiretrovirals as treatment, including HIV pre-exposure prophylaxis (PrEP).
(3) Describe important previous research including clinical trials on the efficacy and
safety of PrEP, especially once daily oral Truvada for this indication.
(4) Explain the rationale behind the Food and Drug Administration (FDA) and Medicines
Control Council (MCC) to approve use of once daily oral Truvada as PrEP.
(5) Detail some of the clinical and logistical issues involved in implementation of
Truvada as PrEP.
(6) Describe previous research on opinions of doctors on prescribing Truvada as PrEP.
(7) Motivate for a need for a study on provider opinions on PrEP in South Africa.
SEARCH STRATEGY: 
The search strategy employed involved an unsystematic search of Pubmed using the search 
terms as below: 
((HIV vaccine) AND failure) AND (“2” [Date-Publication]:”3000”[Date-Publication] 
HIV PrEP and knowledge; (HIV PrEP) AND acceptability; ((HIV PrEP) AND adherence) 
AND efficacy; South African women AND HIV PrEP; (Questionnaires) AND HIV PrEP; 
((gaps) AND research) AND HIV PrEP 
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Provider knowledge about HIV PrEP; physicians attitudes about HIV PrEP; provider 
practices about HIV PrEP; doctor practices about HIV PrEP; survey HIV PrEP; FDA 
approval Truvada PrEP; cost-effectiveness of PrEP; adolescents AND PrEP; RV144. 
A search on Google was also performed for “HIV in South Africa” and “population in 
provinces in South Africa”. 
 
LITERATURE SUMMARY: 
Background: need for HIV PrEP 
Relevant HIV statistics 
To start off with, HIV is still an important problem that needs intervention in today’s 
modern world. To illustrate this point, the following statistics on HIV are given in the 
references discussed below.  
Globally, WHO estimates that 34.3 million adults were living with HIV in 2014, of which 
17.4 million were women.. Furthermore, 1.8 million adults were newly infected, and 1 
million adults died in 2014. 1 
Stats SA estimates that over 458933 deaths occurred in South Africa in 2013 and that 51.2% 
of these deaths are found in the 15 to 59 year age groups. The article also shows that HIV 
gave rise to 17338 deaths (3.4%) in 2011 and this increased to 23201 deaths (5.1%) in 
2013.2  
Prevalence rates of HIV in South Africa in 2012 vary by province as follows in descending 
order: 
Kwazulu Natal with 16.9%, Mpumalanga with 14.1%; Free State with 14%; North West 
Province with 13.3%; Gauteng with 12.4%; Eastern Cape with 11.6%; Limpopo Province 
with 9.2%; Northern Cape with 7.4% and Western Cape with 5%. 
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South African women are also affected disproportionately by HIV with the prevalence in 
this group aged 15 to 49 being 18.99% while those for adults at same age range is 16.59%. 
Adolescents also contribute significantly to the HIV burden with a prevalence of 5.59%.3 
 
Limited success of antiretrovirals 
 “Physicians now have approximately 30 antiretroviral products” which coupled with 
diagnostic modalities like PCR have decreased the prevalence and incidence of HIV/AIDS.  
 
To illustrate this decrease, the following statistics are pertinent: 
HIV/AIDS was the leading cause of death in the 25 to 44 year age group in 1995 in the US, 
resulting in 32000 deaths or 20% of all deaths in this age group. By 2005, this had 
decreased to 6000 deaths or 5% of all deaths in this age group. Also, HIV positive patients 
live up to 14 years longer as a result of widespread antiretrovirals. 
 
“Access to antiretroviral agents also leads to improvements in outcomes for HIV-1/AIDS 
patients in resource-poor countries.” 4 
Despite these successes several challenges still remain. 
 
(1) Increased mortality despite HAART can still occur in people with common comorbid 
conditions. For example, a study, found that 15 out of 102 participants with concomitant TB 
died (15%),while 41 out of 1413 patients with no concomitant disease died (3%).  
(2) Pre- and post-integration latency.  
“As a rule, viral rebound follows discontinuation of therapy, and on that account, therapy 
must be undertaken for a lifetime.” 4 
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(3) HIV is now considered a chronic disease. HAART with extended survival can result in 
long-term sequelae, which need to be managed. “In this context, ….. which can in turn 
increase the risk for developing heart disease and type 2 diabetes”. 4 
(4) Treatment of paediatric HIV patients remains problematic. 4 
(5) Despite our successes, the WHO statistics mentioned above are sobering. 1  
 
Failure to develop an HIV vaccine 
Allied to HIV still significantly contributing to global mortality despite wider use of 
antiretrovirals, is the failure to develop an effective candidate vaccine, despite decades of 
research.  
Only the RV144 clinical trial testing “canarypox recombinant vector vaccine ALVAC-HIV 
(vCP1521) and recombinant gp120 AIDSVAX B/E administered in a prime-boost HIV 
vaccine regimen showed a reduction of HIV incidence of 31%  in the vaccine compared to 
the placebo group in 2009,5 and only recently did a candidate subtype C gp140 vaccine 
primed by SAAVI DNA-C2 and boosted by MVA-C HIV  vaccine show CD4 and CD8 T-
cell responses of “74% and 32% of the participants, respectively in April 2016..”6 
Challenges involved in development of an HIV vaccine 
There are several challenges involved in the development of an HIV vaccine. These include: 
(1) the “exact  immune correlates of natural HIV protection are poorly defined 
(2) extensive genetic diversity of HIV subtypes (3) need for HIV vaccines for Africa to be 
capable of inducing specific CD4 T-cell responses that enhance both CD8 T-cell and 
humoral antibody responses, (4) need for HIV vaccines to induce a good mucosal T and B-
cell response7   
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All the above, underscores the fact that investigating other HIV prevention methods other 
than vaccines is still of paramount importance, including HIV PrEP. 
Efficacy of  HIV PrEP: successes 
 
Several studies using either Tenofovir or Truvada as HIV PrEP, either taken orally or used as 
a microbicide gel have been conducted. The most noteworthy are detailed below: 
 
The CAPRISA004 study  was conducted in May 2007 to March 2010 in Kwazulu-Natal, 
South Africa. Enrolled women were randomized to 2 arms: tenofovir gel or placebo gel. 
Results showed that use of a peri-coital microbicide gel in 889 South African women 
produced a “reduction of HIV incidence of 54% in high gel adherers, and 38% and 28% in 
intermediate and low gel adherers”. 8 
The multinational iPrEx study involved 2499 men who have sex with men, conducted from 
July 2007 through December 2009, who were assigned randomly to receive either Truvada or 
placebo. Out of 100 seroconverters, 36 became infected in the Truvada group, and 64 became 
infected in the placebo group, giving an efficacy of 44%. 9  
The Partners PrEP study conducted from July 2008 through November 2010 in Kenya and 
Uganda involved 4747 heterosexual serodiscordant couples. The HIV negative participants 
were randomized to receive once-daily tenofovir, Truvada or placebo. There was a 67% 
reduction in HIV incidence  using oral tenofovir, and a 75% reduction in HIV incidence using 
oral Truvada, relative to placebo. 10  
The CDC 4940 (TDF2) study involving 1200 men and women in Botswana  taking once-
daily oral Truvada showed an efficacy ( reduction in HIV incidence compared to placebo) of 
62%. 11  
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The Bangkok Tenofovir study involving 2413 men and women who injected drugs in 
Thailand showed a 66% efficacy ( reduction in HIV incidence compared to placebo) using 
once-daily oral Truvada as HIV PrEP. 12 
 
Efficacy of HIV PrEP: failures 
In contrast, however, some studies testing use of tenofovir or Truvada as HIV PrEP showed 
no efficacy.  
An example of these are the FEM-PrEP study  involving 1950 women from Africa, Kenya, 
and Tanzania conducted in June 2009 through April 2011, who were randomized to receive 
either Truvada or placebo. The study showed a 6% efficacy ( 33 HIV infections in the 
Truvada group and 35 in the placebo group).13 
Another example is the VOICE study involving 5029 women from South Africa, Uganda, 
and Tanzania conducted from September 2009 through June 2011.The participants were 
randomized in a 1:1:1:1:1 ratio into 5 groups: oral tenofovir with Truvada placebo, oral 
Truvada and tenofovir placebo, oral tenofovir placebo with Truvada placebo, vaginal 1% 
tenofovir gel and vaginal placebo gel. 312 seroconversions occurred in the study and were 
included in the primary analysis, yielding 52 in the tenofovir group, 61 in the Truvada group, 
61 in the tenofovir gel group, 60 in the oral placebo group, and 70 in the placebo group. The 
efficacy was thus -4.4% for once-daily oral Truvada, -49% for once-daily oral tenofovir, and 
15% efficacy for daily vaginal tenofovir gel use. 14 
 
Adherence as explanation for discrepancies in efficacy 
One of the most plausible explanations for the discrepant results noted in these trials is 
substantial differences in adherence to the study regimens.  
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To show evidence for this statement, the adherence statistics in each of the trials mentioned 
above is illustrated below: 
For the studies which demonstrated efficacy, the CAPRISA004 study recorded 72.% of sex 
acts covered by use of tenofovir gel before and after coitus and was similar in either gel or 
placebo group; 8 the iPrEx study recorded self-reported pill use and stable use of drug from 8 
weeks post-enrollment measured by pill count of at least 89% in each group; 9 the Partners 
PrEP study indicated by pill count that at least 97% of tablets in either group were taken , 10
TDF2 study showed adherence rates of 81%, 11 and the Bangkok Tenofovir Study showed 
adherence rates of 66%.12 
In contrast, for the studies which demonstrated no efficacy, adherence rates for the FEM-
PrEP study was 7 out of 27 ie 26% for women who seroconverted as measured by plasma 
tenofovir level, 13 and for the VOICE study mean plasma tenofovir was 29% for Truvada use, 
30% for tenofovir use and 25% for vaginal tenofovir gel use. 14 
A graphical representation showing the linear relationship between the degree of adherence 
versus the efficacy is shown below: (ref 20) 
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The correct conclusion thus seems to be that HIV PrEP is efficacious, but that the efficacy 
depends on adherence of patients or participants. 
 
Safety data on HIV PrEP 
The studies also showed that use of Truvada or tenofovir as HIV PrEP was reasonably safe. 
The safety data is as follows: 
CAPRISA004 showed “Coitally-related tenofovir gel use was safe. There were no increases 
in renal, hepatic, pregnancy-related or genital adverse events” with only increased diarrhoea 
noted as an adverse event possibly related to the gel.8 iPREx showed “In testing for 
elevations in serum creatinine levels, there were 41 instances of elevations that were at least 
1.1 times the upper limit of the normal range or more than 1.5 times the baseline level”9 
resulting in 10 permanent discontinuations of study drug. All these creatinine elevations were 
however reversible, with study drugs being restarted in 9 subjects. 
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Nausea also occurred more in the exposed as opposed to the placebo group. 9 Other adverse 
events noted in these trials were: 
 Statistically significant declines in bone mineral density in the TDF2 study 
 “Pre-existing HIV infection” documented in every study PrEP study 
 Development of “treatment related resistance” in “ a small amount of HIV 
seroconverters”, mainly resistance mutations implicated in emtricitabine resistance 15 
Additional data shows that HIV PrEP including other PrEP modalities may be efficacious and 
safe: 
(1) HPTN067 randomized 179 Cape Town based women to use of TDF/FTC daily, twice 
weekly with post-sex cover, and before and after sex. Results showed only 1/60 
participants; and 2/60 and 2/60 participants respectively in each group seroconverted. 
Adherence was lower however in the time-driven and event-driven groups ( 76%, 
65% and 53% respectively).29 
(2) The PROUD and IPERGAY studies enrolled men who have condomless anal sex in 
trials in the United Kingdom and France respectively, and randomized them to once 
daily TDF/FTC or placebo. Results indicated a relative risk reduction of TDF/FTC 
versus placebo of 86%.30,31 
(3) MTN020 and IPM027 tested the efficacy and safety of a monthly Dapivirine ring 
versus placebo, and showed a relative risk reduction of HIV-1 of Dapivirine versus 
placebo of 27% ( 95% CI 1 to 46 p=0.046) and 30.7% (95% CI 0.90 to 51.5 
p=0.0401)31 
(4) The Partners Demonstration Project involving administering antiretrovirals to the HIV 
positive partners in serodiscorant couples, and PrEP to the HIV negative partners 
showed only 5 incident infections out of 1013 participants, far below the projected 63 
infections.30 
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(5) Long-acting injectable PrEP regimens involving rilpivirine, maraviroc and 
cabotegravir have to date also been safe and well tolerated. 31 
(6) Caution, however, needs to be exercised in certain situations regarding PrEP use as 
has been demonstrated in some clinical trials. The IPrEx open-label extension 
suggested that long-term exposure to TDF/FTC as PrEP may be associated with 
declining renal function over time30, the US Demo Project showed that more careful 




Regulatory body approvals for Truvada as HIV PrEP 
 Given the public health importance of finding HIV prevention or treatment modalities to 
supplement the existing HAART regimens, the lack of success in developing an HIV vaccine, 
and the available evidence, the FDA approved use of oral daily Truvada as HIV PrEP on 16 
July 2012. 16 
 
Release of guidelines on use of HIV PrEP 
 
FDA registration of PrEP was further backed up in the United States by the release of 
guidelines developed by the Centres of Disease Control (CDC), detailing the indications for 
prescribing PrEP, allied monitoring and counselling, and special considerations (for example, 
interactions with other medications) in 2014. 17 
 
Guidelines for use in males who have sex with males (MSM) were released in South Africa 
prior to the CDC guidelines. 18  
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The World Health Organization (WHO) conducted a review of 12 randomized controlled 
trials on the effectiveness of oral PrEP, agreed that level of protection offered by PrEP is 
strongly correlated to adherence, and that “use of daily oral pre-exposure prophylaxis (PrEP) 
is recommended as a prevention choice for people at substantial risk of HIV infection.” 
Substantial risk was defined as risk leading to an incidence of HIV infection in the absence of 
PrEP that is sufficiently high (>3% incidence) to make offering PrEP potentially cost-
effective.These risk groups included MSM, transgender women and uninfected partners in 
serodiscordant couples.28  
Review of all these guidelines has now culminated in the Medicines Control Council in South 
Africa approving HIV PrEP as a registered medicine in South Africa. 19 Previously PrEP was 
only prescribed off label in South Africa. More recently in February 2016, the updated 
“Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of 
acquiring HIV infection” were released, which now covers both MSM and other people at 
risk of HIV.20  
 
Despite the evidence for the efficacy of PrEP, there are several issues that clinicians need to 
be aware of when trying to implement these new PrEP guidelines. 
 
 
Issues associated with prescribing PrEP 
One of the first issues is awareness of the appropriate indications for prescribing PrEP. 
In this regard, the CDC and updated South African guidelines are very detailed, and each 
have a list of indications for prescribing PrEP for MSM , intravenous drug users, and 
heterosexuals.17,20  
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Some of the clinical issues identified by both guidelines include: 
(1) Mandatory baseline investigations including renal function tests, hepatitis B surface 
antigen (HBsAg) and hepatitis B surface antibody (HBsAb) and a sexually 
transmitted infections (STI) screen17,18,20  
(2) Recommended medications for HIV PrEP only include tenofovir and Truvada 17 
(3) Regular monitoring needed. Similar clinical monitoring schedules are mentioned in 
all guidelines, requiring monitoring of clients at screening, initiation of HIV PrEP, 1 
month, 4 months post-initiation and 6-monthly STI screen and annual renal function 
screening. 17,18,20 
(4) Only clients with a creatinine clearance of 60ml/min or more should be started on 
PrEP 17,18,20 
(5) Need to treat gastrointestinal symptoms and other minor side effects symptomatically 
18,20 
(6) Close monitoring for major side effects, for example, renal failure hinted at above or 
bone mineral density decrease, especially in persons with a family history of 
osteoporosis or pathological fractures 17,18,20 
(7) Need to monitor for acute flare-ups of hepatic dysfunction when tenofovir or Truvada 
is withdrawn in patients with chronic active hepatitis, for example, due to poor patient 
adherence. 17,18,20  
(8) Need to attempt to prevent HIV medication resistance as much as possible by 
withdrawing HIV PrEP if symptoms and signs consistent with acute HIV 
seroconversion syndrome is noted in a patient. 18,20 
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Thus counselling to ensure that the patient remains motivated and adherent is of paramount 
importance. Strategies to achieve high adherence levels and prevention of increasing risky 
behaviour (risk compensation) while on PrEP is thus mentioned in all guidelines. 
These strategies include: 
(1) Need for an individualised risk benefit assessment to assess participant eligibility for
PrEP 17,18,20
(2) Need for implementation of risk reduction counselling together with adherence
counselling at all follow-up visits. 18,20 To this effect, the guidelines have also given
an series of strategies  toward improving medication adherence. 17,20
(3) It is to be noted that the new South African guidelines talk about “effective use” and
not adherence, as these guidelines do not envisage that people will use HIV PrEP
lifelong as with antiretrovirals used therapeutically, but only during periods in their
lives where their risk of HIV acquisition is high.20
Previous research on provider opinions regarding PrEP 
Due to the fact that PrEP is highly dependant on good adherence for efficacy,  as shown by 
the clinical trials described above, and that the successful implementation of PrEP requires 
knowledge of PrEP and attendant medical and other issues and commitment by physicians 
several studies were done to assess physician readiness to prescribe PrEP mainly in the 
United States. These studies were conducted prior to the FDA decision to approve Truvada as 
PrEP and the later release of the CDC guidelines. 
These studies show that under 50% of American physicians are willing to prescribe PrEP. 
21,22 The studies, both quantitative and qualitative, also show several perceived barriers to 
PrEP implementation including logistical concerns associated with monitoring, a feeling that 
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more research still needs to be done to show efficacy, perceived medical risks such as 
increased HIV resistance if patients become HIV infected, and concerns about patient lack of 
adherence and possible risk compensation. 21,22,23 
 
To elucidate further on these concerns and barriers expressed by clinicians in previous 
surveys, the following factors were noted to reduce potential provider willingness to 
prescribe PrEP: 
(14) Lack of knowledge of oral PrEP. Surprisingly, 16.5% of providers in a 
Canadian survey were not familiar with PrEP 21 and 57.5% of healthcare providers in 
a physician survey conducted in Lima, Peru were aware of PrEP 22 
(15) Belief that the existing evidence from clinical trials was insufficient to justify 
widespread prescription 21 
(16) “Lack of clarity regarding which patient populations were appropriate for 
PrEP” 21 
(17) belief by providers that adherence to PrEP would be substantially less in real-
world as  
            opposed to clinical trial settings, thus significantly compromising its effectiveness. A 
            concern was also expressed that this would particularly apply to high-risk patients.   
            23 
(18) concern about time constraints in busy general practices making adherence 
and risk 
reduction counselling suboptimal 23 
(19) concern about patients not accurately disclosing their sexual behaviour 
patterns, thus causing providers to potentially miss indications to prescribe PrEP in 
some cases 23 
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(20) concerns about the high costs of the medication, limiting patients’ ability to 
access Truvada as PrEP 22,23 
(21) concerns about medication related toxicities, and the belief that patients on 
PrEP would have a far lower tolerance for these given the fact that they are healthy 
and HIV negative 23 
(22) concerns about HIV medication resistance 22,23 
(23) concerns about patient risk compensation ie engaging in more risky behaviour after 
starting PrEP 23 
(24) Inexperience in dealing with the demands created by prescribing PrEP 21 
(25) the so-called “Purview Paradox” where HIV specialists tended to believe that PrEP 
should be prescribed by general practitioners as most patients seen by HIV 
specialists are already HIV positive and do not need PrEP, while in contrast the 
general practitioners felt that the HIV specialists were more equipped to deal with 
the monitoring and counselling demands engendered by prescribing PrEP 23 
(26) Perception by clinicians that potentially eligible clients were not interested in 
starting PrEP 21,23 
 
The studies, however, also pointed out several factors that the participating physicians 
identified would potentially facilitate their willingness to prescribe PrEP. 
These factors include: 
(4) belief in the efficacy of PrEP based on previous clinical trial data would create a sense 
of duty in physicians to prescribe it, despite the problems mentioned above 21,22,23 
(5) patient motivation, more specifically, patients who were empowered enough to ask 
physicians about PrEP 23 
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(6) presence of normative guidelines such as those eventually published by the CDC and 
knowledge that respected peers have already started prescribing PrEP 22,23 
 
All the research studying physician readiness to prescribe PrEP seems to have been 
conducted in the US. As South Africa has the highest HIV rate in the world, and PrEP is a 
powerful tool for prevention of HIV, cooperation of and knowledge of South African doctors 
or other prescribers is vital to ensure that implementation of existing PrEP guidelines is 
successful.  
Controversies surrounding HIV PrEP 
 
Since the approval of Truvada as PrEP and the attendant guidelines, several non-clinical 
issues have been raised related to implementation. Some of these issues include cost-
effectiveness of scaling up Truvada as PrEP, and the case for investment required for 
implementation, particularly in South Africa. 
In the South African TB and HIV Investment Case Report24 PrEP for sex workers, discordant 
couples, adolescents and microbicides was discussed. The report identified unit costs and so-
called “Technical Efficiency” factors for these and other interventions. The available 
evidence suggests that “once daily Truvada is needed to offer protection from HIV.”24 
Ensuring adherence was identified as a key Technical Efficiency factor, and the importance 
of effective adherence counselling was highlighted.  
The existing and future health budgets will have to cover the costs of scaling up interventions 
such as PrEP, and cost-effectiveness of PrEP programs has thus become a major point of 
discussion. 
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Pretorius et al.25 highlight that even assuming that PrEP will cost $150 per year per person, as 
compared to antiretrovirals costing $600 per year per person, “expanding ART would still 
prove more effective in terms of cost per infection averted”, and that the cost would be 
$12500 to $20000 per infection averted from 2014 to 2025. The cost-effectiveness would be 
adversely affected if antiretroviral coverage and behavioural disinhibition increases during 
scale up of PrEP.25 
To counter this cautious viewpoint, targeting high risk groups was however identified as 
enhancing the effectiveness of any PrEP program, and being more cost-effective.24 Thus 
allied to the MCC decision on PrEP, the South African Minister of Health in his budget 
speech on 10 May 2016, approved administering oral Truvada as PrEP in selected 
countrywide sex worker programmes along with universal access to testing and treatment.26 
Other observers, notably Professor Bekker et.al27 have noted that adolescents constitute 
another vulnerable group, as seen by the HIV prevalence of 5.59% noted previously.3 A 
number of reasons such as power inequality particularly with intergenerational sex, and 
intimate partner violence have been given for this vulnerability. However, studies such as the 
ADAPT study involving regimens comprising self-administered daily, event-driven and 
intermittent Truvada as PrEP showed similar adherence between younger and older 
participants. This group therefore advocates more research and availability of PrEP for this 
vulnerable group.27 
 
Motivation for proposed study 
There is thus a need for a survey that measures the willingness and attitudes of South African 
doctors and other types of providers to prescribe PrEP. 
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The survey thus tests opinions of South African doctors on Truvada as PrEP, and tries to 
ascertain whether clinical and/or non-clinical issues that could relate to the technical 
efficiency factors noted above affect willingness to prescribe PrEP on the part of South 
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Recent clinical trials has demonstrated the efficacy of use of Truvada as pre-exposure 
prophylaxis (PrEP) in preventing HIV infection. The Medicines Control Council accordingly 
approved use of once daily Truvada as PrEP in December 2015. To date no African studies 
have been done measuring knowledge and attitudes of clinicians on this topic.  
Methods 
Thus, an online survey was administered from 21 June till 14 July 2016, inviting doctors on 
the South African Medical Association database, a subset of all South African doctors who 
are all required to be registered with the Health Professions Council of South Africa 
(HPCSA) to participate.  
Results 
289 out of  14325 doctors (2%) responded to the survey. Results show that approximately 
74% of respondents were  willing to prescribe Truvada as PrEP. Hypothesis testing showed 
that provider willingness to prescribe PrEP was associated with serving a relatively high 
proportion of MSM patients, self-identification as an expert in HIV care and being questioned 
about PrEP by at least one patient.  All respondents rated efficacy, development of HIV 
resistance, compliance of patients, and logistics of monitoring for clinical complications as 
major concerns in deciding to prescribe PrEP to patients. Other concerns noted included 
possible sexual disinhibition of patients, access to PrEP for patients and cost-effectiveness, 
particularly in those doctors who were ambivalent about prescribing Truvada as PrEP. 
Certain facilitating factors were also noted by the respondents as potentially having the effect 
of increasing their willingness to provide Truvada as PrEP, namely availability of qualified 
counsellors for adherence counselling, availability of nurses to assist with clinical monitoring 
of patients, and more continuing medical education on PrEP.   
Conclusions 
South African doctors are willing to face the challenge embodied in implementation of 
prescribing Truvada as PrEP. 
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Despite our modern advances, HIV remains a challenging problem which has eluded all 
attempts to find a cure or suitable vaccine. 
Thus, a number of other approaches, notably use of  Truvada as pre-exposure prophylaxis 
(PrEP) have been attempted to prevent HIV in people at risk. 
 
Recent evidence have suggested that this approach is efficacious. Examples of studies that 
have demonstrated this include  the iPrEx study that showed a reduction in HIV of 44% 
compared to placebo[1], the Partners PrEP study that showed a 67% reduction in HIV 
incidence  using oral tenofovir, and a 75% reduction in HIV incidence using oral Truvada, 
relative to placebo[2] , the TDF2 study that showed an efficacy of 62%,[3]  and the Bangkok 
Tenofovir study that showed a 66% efficacy incidence compared using once-daily oral 
Truvada as HIV PrEP. [4] 
As a result of these and other studies the Medicines Control Council (MCC) in South Africa 
opted to approve the use of Truvada as PrEP in December 2015.[5]  This coincided with the 
release in February 2016 of  the “Southern African guidelines on the safe use of pre-exposure 
prophylaxis in persons at risk of acquiring HIV infection”.[8] 
 
The guidelines highlight several clinical concerns that clinicians prescribing Truvada as PrEP 
need to be aware of including monitoring of renal function, bone mineral density, and the 
importance of monitoring of and ensuring good adherence. Thus motivated and informed 
clinicians will be crucial to ensuring success of the Truvada PrEP regimen for patients. 
 
To date, there has not been many studies that assessed knowledge and opinions of doctors on 
prescribing PrEP, and most have been performed in developed countries notably 2 studies 
involving a quantitative survey of physicians in Canada[6] and a qualitative survey of 
American physicians[7]. No African equivalent to these studies has to date been done. 
This study, which is a quantitative survey of South African doctors, was thus designed to 
attempt to address this research gap.   
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The primary objective is to establish the willingness of South African  based doctors 
to prescribe HIV PrEP, with subsequent analyses performed to ascertain the 
association of putative predictor variables such as doctors serving a high proportion of 
high risk HIV negative patients with willingness to prescribe PrEP. The method by 




Doctors who were members of the South African Medical Association (SAMA) were invited 
to take an online survey, and responses collected from 21 June 2016 till 14 July 2016, using a 
sampling frame of doctors belonging to the South African Medical Association (SAMA), ie a 
proportion of total South African doctors registered with the Human Professions Council of 
South Africa (HPCSA).. 
Ethical approval for the study was obtained from the University of Cape Town Human 
Research Ethics Committee (Appendix 6). The presentation of the research was optimized 
according to Journal of the International AIDS Society guidelines (Appendix 7). 
Sample size required was calculated at 97, using the following formula: 
n= p*(1-p)*z2/d2 where  p is the anticipated population proportion , d= precision required on 
either side of the proportion, and z = the cutoff value of the Normal distribution.[9] 
 
As per the Tan paper [6] the online questionnaire was divided into domains eliciting the 
willingness to prescribe Truvada as PrEP, demographic details of the doctors; their 
knowledge on PrEP; their perception of barriers, concerns and facilitating factors associated 
with their willingness to prescribe Truvada as PrEP as rated using Likert scales; and their 
perceived learning needs. 
 
These responses were then analysed using STATA12, and graphical representation of the 
analyses of opinions expressed on provision of PrEP and perceived barriers to prescribing 
PrEP were plotted using Excel 2010. 
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Testing of main hypotheses was also performed using chi-squared tests to test association of 
provider willingness to prescribe PrEP against proportion of patients who are males who have 
sex with males (MSM), and high risk HIV negative patients. The association between 
willingness to prescribe PrEP was also tested against being asked about PrEP by a patient, 
self-identification as an HIV expert, amount of  reduction in HIV incidence using PrEP that is 
the minimum acceptable, and the so-called “purview paradox”7 where doctors feel that it is 
not their responsibility to provide PrEP. 
Predictor variables where applicable, were dichotomized as follows for the hypothesis 
testing: 
Less than 40% and at least 40% HIV positive patients served, the same categories for 
proportion of HIV negative patients served, and less than 60% and at least 60% for minimum 
acceptable efficacy. 
A similar method was used to conduct exploratory hypothesis testing in order to accomplish 
the secondary objectives outlined above. Similarly, predictor variables were dichotomized 
where applicable, namely less than 3 years or at least 3 years independent practice. 
A logistic regression using a forward selection procedure was performed on the observations 
generated by the survey respondents, and observations with missing data excluded using a 
complete case analysis approach.  
Both the hypothesis testing and logistic regression were performed using STATA12. 
Results: 
Amount of respondents 
289 out of 14325 doctors who were SAMA members responded ie a 2% response. 
Demographics 
The following demographic characteristics were noted, as detailed in Table 1: 
Most doctors were from provinces with a high degree of urbanization, for example, Western 
Cape, Gauteng and Kwazulu Natal. 
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Sex of the respondents were relatively evenly distributed with 55.06% being female, and 
44.94% being male.  
Most of the doctors were also general practitioners, and about 69% work in the public sector, 
with approximately 60% being independent practitioners for more than 5 years. 
The mean proportion of HIV positive patients served by the responding doctors was 37.70%, 
while the mean proportion of high risk HIV negative doctors served was 32.28%. 
Willingness to prescribe 
Of the responding doctors, approximately 74% expressed a willingness to prescribe Truvada 
as PrEP, with approximately 26% being undecided or unwilling to prescribe Truvada as HIV 
PrEP. 
Gratifyingly, although 26 doctors (9%) did not know about Truvada being approved as PrEP, 
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Table 1: Univariable analysis for South African doctor survey on HIV PrEP 
 
Question Description Number Total % 
Demographics  
Location of practice Western Cape 49 245 20.00 
 Gauteng 75 245 30.61 
 Eastern Cape 27 245 11.02 
 Kwazulu Natal 46 245 18.78 
 North West Province 12 245 4.90 
 Mpumalanga 12 245 4.90 
 Free State 10 245 4.08 
 Limpopo 8 245 3.27 
 Northern Cape 6 245 2.45 
     
Sex Male 111 247 44.94 
 Female 136 247 55.06 
     
Type of physician Infectious disease specialist 2 246 0.81 
 Non-specialist in infectious 
diseases 
243 246 99.19 
     
 Specialist in HIV care 55 246 22.36 
 Non-specialist in HIV care 191 246 77.64 
     
Type of practice Private sector 77 246 31.30 
 Public sector 169 246 68.70 
     
% time spent on 
activities 
Mean time spent on clinical 
activities (%) 
N/A 242 73.71 
 Mean time spent on research 
activities (%) 
N/A 238 4.65 
     
Experience Independent practise for >=5 
years 
146 242 60.34 
 Independent practise for <5 
years 
61 242 25.20 
 Intern/ community service 35 242 14.46 
     
Distribution of 
patients 
Mean proportion HIV positive 
(%) 
N/A 243 37.70 
 Proportion high risk HIV 
negative (%) 
N/A 236 32.28 
Opinions about HIV PrEP 
Willingness to 
prescribe PrEP 
Yes 157 213 73.71 
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 Maybe 51 213 23.94 
 No 5 213 2.35 
Familiarity with PrEP 
Current 
knowledge 
Very familiar 39 246 15.85 
 Limited familiarity 181 246 73.58 
 No familiarity 26 246 10.57 
 
 
Familiarity with PrEP 
Approximately 16% of respondents felt they were very familiar with HIV PrEP in general, 
74% expressed some knowledge of HIV PrEP and the results from clinical trials, and 11% 
expressed a lack of familiarity with Truvada being used as HIV PrEP (Table 1). 
 
Statements about PrEP 
Fig 1 graphically shows the opinions responding doctors expressed regarding prescribing 
Truvada as PrEP.  
The results are consistent with the high percentage of doctors willing to prescribe PrEP, with 
most doctors subscribing to the positive statements about PrEP, and very few to the negative 
statements, with one exception. 
This was the statement that provision of PrEP may lead to the “medicalization” of HIV 
prevention, which 57% of the respondents endorsed. 
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    Fig 1: Opinions of South African doctors regarding PrEP 
Main hypothesis testing 
Testing of hypotheses yielded the following significant predictor variables associated with 
provider willingness to prescribe PrEP, as shown in Table 2: 
self-identification as an expert in HIV care (OR=3.31,p=008); serving at least 40% males 
who have sex with males (MSM) (OR=2.26,p= 0.049); being asked about PrEP by a patient 
(OR=2.77, p= 0.007) and rating efficacy as most important in the question asking about 
efficacy as a Likert scale (OR=3.29,p=0.000). 
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Table 2: Summary table of main hypothesis testing 
 




Odds ratio Chi-squared p-value 
Self-identified expert in HIV 
care 
45 6 
3.31 7.14 0.008 
Non-expert in HIV care 111 49    
      
>= 40% HIV positive  
patients 
73 24 
1.10 0.09 0.765 
<40% HIV positive  
patients 
83 30 
   
      
>= 40% high risk HIV negative 
patients 
51 21 
0.75 0.74 0.390 
<40% high risk HIV negative 
patients 
100 31 
   
      
>= 40% MSM  43 8 2.26 3.89 0.049 
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Being asked by patient about 
PrEP 
68 11 
2.77 7.31 0.007 
No patients asked about  
PrEP 
76 34 
Efficacy rated as most 
important concern 
114 25 
3.29 14.27 0.000 











Odds ratio Chi-squared p-value 
PrEP should be given in 
dedicated PrEP clinics 
19 59 
1.18 0.26 0.608 
PrEP should be given by general 
practitioners 
36 132 
Exploratory hypothesis testing 
Exploratory hypothesis testing, yielded the following variables associated with willingness to 
prescribe Truvada as PrEP, as shown in Table 3 : 
At least 40% work time spent in Public Health (OR=3.21, p=0.033), knowledge about PrEP 
obtained from conferences (OR=4.75, p=0.000), knowledge about PrEP obtained from 
journals (OR=3.05, p=0.002) and from seminars (OR=2.33, p=0.018). 
Associations with borderline significance included: 
male sex, independent practice for at least 3 years, and resistance and disinhibition identified 
as most important when answering questions on a Likert scale. 
Internal consistency of survey 
Table 3 shows an association of provider willingness with belief in patient benefit (OR= 4.34, 
p=0000) and belief in the correctness of the MCC decision (OR=6.38, p=000).  
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Table 3: Summary table of exploratory hypothesis testing 
 









      
Female sex  
 
82 37 0.56 3.21 0.073 
Male sex 75 19    
      
>=3 Years of practise 
 
109 30 1.82 3.35 0.067 
<3 years of practise 
 
46 23    
      
      
>=40% spent in public health 
 
31 4 3.21 - 0.033* 
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<40% spent in public health 116 48    
      
      
Knowledge about PrEP from  
journal 
67 11 3.05 9.43 0.002 
Knowledge from other 
sources or no previous 
knowledge 
90 45 
   
      
      
Knowledge about PrEP from  
conferences 
57 6 4.75 12.98 0.000 
Knowledge from other 
sources or no previous 
knowledge 
100 50 
   
      
Knowledge about PrEP from  
seminars 
61 12 2.33 5.56 0.018 
Knowledge from other 
sources or no previous 
knowledge 
96 44 
   
      
Belief that MCC was right 
 
137 29 6.38 30.21 0.000 




   
      
      
Belief that patients will 
benefit from  
PrEP 
124 26 
4.34 21.00 0.000 
Belief that patients will not 
benefit 
From PrEP 
33 30    
      




0.56 3.35 0.067 
Resistance rated as 2nd or 3rd 
most  
important 
103 29    
      
Disinhibition most important 
 
33 18 0.56 2.81 0.094 
Disinhibition rated as 2nd or 
3rd most 
important 
124 38    
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0.56 2.89 0.089 
Adherence counselling not an  
Important facilitator 
62 15    
      
Notes:  
 











Barriers associated with prescribing PrEP 
A number of perceived barriers and concerns were asked about in questions employing a 
Likert scale, and the results are as below: 
Mirroring the hypothesis testing results from Table 2 and Table 3, efficacy, resistance and 
disinhibition showed the greatest differences between those willing and those more 
ambivalent about prescribing PrEP in Figure 2. 
Of those respondents who were willing to prescribe Truvada as PrEP, approximately 80% 
rated efficacy as most important, while 52% of the more unwilling doctors did so.  
Of those willing to prescribe, 43% rated resistance as most important, while 56% of those 
more unwilling did so. Similarly 37% of those willing to prescribe rated disinhibition most 
important, while 58% of those less willing did. 
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In both groups of doctors, a similar number rated side effects, monitoring for complications, 
and patient compliance as most important. 
Other non-clinical factors were rated as most important differently in each group: 
26% rated cost-effectiveness in the willing group, compared to 36% in the other group, and 
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Fig 2: Plot of willingness to prescribe PrEP versus perceived barriers 
Figure 3 shows the means of PrEP efficacy acceptable to doctors, with 60% minimum 
efficacy required by those willing and maybe willing to prescribe PrEP, and 40% minimum 
efficacy required in the “No” group. One-way ANOVA however revealed that this difference 
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Bartlett’s test for equal variances: chi-squared= 3.3435, p=0.188 
__________________________________________________________________________ 
 





Exploratory hypothesis testing as in Table 3 showed no significant associations between 































Doctor willingness to prescribe PrEP
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by a trained counsellor showed a borderline association with doctor willingness to prescribe 
PrEP (OR=0.56, p=0.089). 
 
Logistic regression 
Finally a logistic regression was performed, and run on the observations for 60 participants, 
using a complete case analysis approach, as shown in supplemental Table 4 which shows the 
model building procedure using likelihood ratios (threshold p-values=0.05 for inclusion into 
model and p=0.1 for exclusion).  
This model yielded very imprecise coefficient estimates probably due to the small sample 
size, and only time spent in research work and teaching both in 10% increments were 






























Factors associated with provider willingness 
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The results yielded some interesting data, from which several conclusions which have 
clinical, and policy implications can be drawn. 
This sample shows a relatively large amount of doctors willing to prescribe Truvada as PrEP, 
namely 157 out of 213 respondents or 74%, as shown in Table 1.  
Further, previous knowledge about Truvada being approved as PrEP did not influence 
provider willingness to prescribe it, although it was a mediating factor in decision making on 
the issue.  
It could also be argued that the high proportion of doctors willing to prescribe Truvada as 
PrEP may be due to SAMA doctors being active in subscribing to journals and attending 
conferences and that this active involvement resulted in them being “early adopters” of any 
new management regimens. 
As the respondents constituted a small proportion of South African doctors, it is difficult to 
comment on whether the results in this preliminary survey were representative of South 
African doctors as a whole.  
Most of the respondents were from urbanized areas such as the Western Cape, Gauteng and 
Kwazulu Natal. This may reflect a higher density of conferences, peer activities and greater 
dissemination of online and written information in urban areas, resulting in greater interest in 
HIV PrEP in the urbanized areas. 
 
Hypothesis testing as in Tables 2 and 3 showed that several factors were identified as 
associated with provider willingness to prescribe PrEP . 
These factors included previous familiarity either with PrEP or antiretrovirals, as shown by 
doctors rating themselves as self-identified expert in HIV care (OR=3.31, p=0.008). 
Peer group learning was also confirmed as an effective mechanism to enhance decision 
making and willingness to prescribe Truvada for even such a novel indication, with strong 
associations with willingness to prescribe PrEP for obtaining knowledge from peer-reviewed 
journals (OR=3.05, p=0.002), conferences (OR=4.75, p=0.000) and seminars (OR=2.33, 
p=0.018). 
 
Perceived patient need for PrEP by the practitioners, as shown by an association of provider 
willingness to being asked by a patient at least once, also played a significant role (OR= 2.77, 
p=0.007).  
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Serving patients who fell into a vulnerable group such as males who have sex with males 
(MSM) was as expected also positively associated with provider willingness to prescribe 
PrEP (OR= 2.26, p=0.049).  
Surprisingly, despite the fact that 62 people in serodiscordant relationships enquired about 
PrEP ( analysis not shown in figures), having at least 40% high risk HIV negative patients in 
doctors’ practices was not strongly associated with provider willingness to prescribe Truvada 
as PrEP (OR= 0.75, p=0.390). A stronger association may, however, be more evident in 







Unlike the result obtained by Dr Kenneth Mayer et. al[7] , a “purview paradox” does not 
seem to exist among South African doctors, as shown in Table 2, with 132 general 
practitioners feeling that PrEP should be administered in any clinic, not dedicated PrEP 
clinics. 
This may reflect the greater perception of the extent of the HIV burden in South Africa and 
the ethical obligation by doctors to provide means to prevent HIV. 
 
Barriers to providing PrEP 
From the hypothesis testing in Table 2, efficacy rated as most important (Question 44), was 
strongly associated with provider willingness to prescribe Truvada as PrEP (OR= 3.29,p= 
0.000). This was also shown in Figure 3, where paradoxically 81% of doctors willing to 
prescribe PrEP rated efficacy as most important, versus 52% of  more ambivalent providers. 
Interestingly enough,  although one-way ANOVA did not show a significant result, Figure 3 
shows a mean efficacy of 60% for Truvada as PrEP as the minimum acceptable level in those 
willing to prescribe PrEP versus 40% in the other group. 
 
This is a little counter to what is expected, but may be explained by the observation that those 
willing to prescribe PrEP are more concerned with efficacy, but less concerned about other 
perceived barriers prescribing PrEP than the more ambivalent group of doctors.. 
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For example, Table 3 shows willingness to prescribe PrEP is borderline negatively associated 
with concern about development of HIV resistance (OR=0.56, p=0.067) and patient 
disinhibition (OR=0.56, p=0.094). Also Figure 2 shows that those 43% of those doctors 
willing to prescribe PrEP regard development of HIV resistance as most important, versus 
56% in the other group. Similarly, 37% of doctors willing to prescribe PrEP rated 
disinhibition as most important, versus 58% in the other group. 
Issues such as monitoring of patients, concerns about patient compliance and side effects 
were not strongly associated with provider willingness to prescribe PrEP. 
However, although not shown to be associated with willingness to provide PrEP on Table 3,  
so-called “efficiency” factors  important to PrEP program implementation[11] may be of 
some concern to providers, and may negatively influence their willingness to prescribe PrEP.  
This is suggested in  Table 1 where 57% of respondents felt that PrEP could detrimentally 
“medicalize” HIV prevention, and also that 49% of responding doctors felt that the patient 
receiving PrEP should pay for it and that only 10% were in favour of a National Health 
Insurance scheme in future incorporating paying for services such as PrEP provision. (data 
not shown on table 1). 
Figure 2 also shows that 26% of those willing to prescribe PrEP rated cost-effectiveness as 
most important versus 36% in the more ambivalent group, and similar percentages for patient 
access to medication at 24% versus 32% respectively. 
Facilitating factors 
Facilitating factors including adherence counselling by trained counsellors, nursing support 
and the need for continuing medical education did not affect provider willingness to prescribe 
PrEP, as shown in Table 3, although adherence counselling was borderline 
significant(OR=0.56, p=0.089) suggesting that those unwilling to prescribe PrEP were more 
concerned about this facilitating factor being present than the more willing group. 
Conclusions 
Limitations of study 
There are several limitations to this study: 
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(1) 2% of the doctors in the SAMA database (289) responded, not surprising given the
facts that the survey was exclusively available online, and that only one email to reach
available doctors was employed. The sample size calculation shown in the Methods
section, though, yielded a total of 97 doctors needed to answer the outcome question
to the required precision, so that the study was adequately powered to answer the
main research question.
(2) Non-responder bias, where doctors who did not take the survey could have differed
regarding willingness to prescribe PrEP from those who did. Volunteer bias could
also have played a role, as the respondents could have been early adopters of PrEP
indicated by the high percentage of doctors willing to prescribe it, and could for
example be more inclined to use online channels as their source of information about
medical topics.
(3) These limitations possibly influenced the generalizability of the results, making these
results very much preliminary.
(4) Social desirability bias where respondents , for example, selectively did not answer
certain questions. This is suggested by the fact that  76 of the 289 survey respondents
(26%) did not answer the outcome question.
(5) Sample size leading to a lack of statistical power.
Suggestions for future studies 
Scope for future studies include: 
(1) Allow all doctors registered with the Health Professions Council of South Africa to
participate.
(2) Use more channels by which to reach potential respondents to a future survey, for
example, journals and seminars as done by Dr Sharma et al[6]
(3) Extending similar surveys to other health professionals, for example, nurses and
counsellors
(4) Use of qualitative studies to more closely look at the impact and valuation of factors
with policy implications such as cost-effectiveness
(5) Recently results of clinical trials involving HIV microbicide rings reported efficacy of
27% for the ASPIRE study[12], and 31% for IPM027[13]. Future surveys could
ascertain doctor willingness to prescribe PrEP in this form.
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Although limited in scope, this study showed willingness on the part of South African doctors 
to prescribe Truvada as PrEP, coupled with reasonably good awareness of the clinical aspects 
of prescribing PrEP and policy implications of the decision by the MCC. South African 
doctors seem to be willing to embrace the potential benefits and also the challenges of a new 
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PART D: APPENDICES 
APPENDIX 1: SAMPLE EMAIL ADDRESSED TO DOCTORS 
To:    Whom it may concern 
Subject:  Truvada approved for HIV prevention in addition to treatment: are you ready? 
Dear  Doctor 
The Medicines Control Council has approved the use of Truvada (tenofovir/emtricitabine) as a 
means to prevent HIV in December 2015. 
More specifically, the MCC has approved the use of once daily oral Truvada as HIV pre-exposure 
prophylaxis (PrEP) ie Truvada taken before an event that exposes the person to HIV, as opposed to 
post-exposure prophylaxis. This decision is based on results from clinical trials showing both efficacy 
and safety of Truvada used for this indication, and follows on from approval of Truvada for this 
indication by the Food and Drug Administration (FDA) in July 2012. 
Coupled with these approvals are the release of guidelines from the Centres for Disease Control 
(CDC) and South African HIV Clinician Society guidelines on indications for, side effects of, and
appropriate prescription of Truvada as PrEP with associated safety monitoring and counselling.
Successful implementation of these guidelines, needless to say, depends on commitment from both 
the patient and motivated, well informed clinicians.  
This survey thus tests: 
(1) Knowledge of clinicians on HIV PrEP
(2) Opinions or beliefs of clinicians on HIV PrEP
(3) Concerns about prescribing HIV PrEP
(4) Any need clinicians feel for further information on PrEP clinical trials and guidelines
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The survey gives an opportunity to obtain further information on request after completion, and also 
the opportunity to enter a draw to win an Ipad.  
At the end of the survey, a link will be provided to download the 2016 South African guidelines on 
use of Truvada as PrEP. A link to email Dr Llewellyn Fleurs to enter a draw to stand a chance of 
winning an Ipad will also be provided at the end of the survey. 
 
It is important to note that although survey participants that send the email to enter the draw will 
no longer be anonymous, it will still not be possible to link your answers to you personally, in any 
way. 
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APPENDIX 2: INFORMED CONSENT DOCUMENT 
INFORMED CONSENT DOCUMENT 
LETTER OF INFORMATION REGARDING  STUDY 
STUDY TITLE: 
Assessing perceptions, beliefs, and readiness of doctors based in South Africa for the 
implementation of HIV pre-exposure prophylaxis. 
INVESTIGATORS: 
Linda-Gail Bekker, MBCHB FRCP PhD, 
Llewellyn Fleurs,   MBCHB BSc (Biochemistry). 
INTRODUCTION 
You are being asked to participate in a research study being conducted by a research team from the 
Desmond Tutu HIV Centre in Crossroads, Cape Town. Before agreeing to participate in this study, it is 
important that you read and understand the following explanation of the study. You are free to 
accept or decline participation in the study without consequence. 
PURPOSE OF THE STUDY 
This questionnaire has been designed to investigate physician knowledge, opinions and learning 
needs regarding pre-exposure prophylaxis (PrEP) for prevention of HIV infection. You do not need to 
have any prior knowledge of PrEP to participate in the survey. 
STUDY PROCEDURES 
• Participation in this study is voluntary. If you agree to participate, you will be asked to fill out this
six page online questionnaire.
• This survey is confidential. Please do not include your name or any other identifying information
other than what is asked in the survey.
• This survey takes about 15-20 minutes to complete and asks you questions about your knowledge
and experience with PrEP, your opinions on key issues and your learning needs.
• You have the option to not answer any questions which you find confusing, uncomfortable or
choose to omit for any reason.
• You also have the option to withdraw your consent by not completing the questionnaire if you so
wish for any reason. If you choose to withdraw, simply exiting from the website which contains the
online survey will delete all your responses and close the survey.
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• All survey responses are deidentified and will remain confidential.  
 Access to the online spreadsheet will be limited to the study investigators and their 
delegates, the Faculty of Health Sciences Human Research Ethics Committee for the purpose 
of monitoring the study, and the survey provider (). The results of this study may be 
presented by the study team at conferences, seminars or other public forums, and published 
in journals. 
• At the end of the survey  a link will be provided to download the 2016 South African guidelines on 
the use of Truvada as PrEP.  A link to email Dr Llewellyn Fleurs to enter a draw to possibly win an 
Ipad will also be provided at the end of the survey. 
It is important to note that although survey participants that send the email to enter the draw will 




There are no known risks associated with participation in this study. 
POTENTIAL BENEFITS 
Benefits to you from participating in this study may include gaining some knowledge of PrEP and 
issues surrounding its use. Other health care providers who serve populations at risk for HIV may 
also benefit from your participation in this study in the future.  
INFORMED CONSENT 
By clicking the box below, you are agreeing that you have read and understood the informed 
consent form and agree to participate in the study. If you require further information about this 
study, you may contact Prof. Linda-Gail Bekker, Principal Investigator, at (021) 406 6970 during 
business hours. This study has been approved by the Research Ethics Board at the University of Cape 
Town. If you have any questions regarding your rights as a research participant, you may contact the 
UCT Office of Research Ethics at 021 406 6338 
Check all that apply 
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APPENDIX 3: SAMPLE INFORMATION PACK FOR DOCTORS THAT REQUEST MORE INFORMATION 
ON  HIV PrEP 
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APPENDIX 4: SAMPLE QUESTIONNAIRE ASSESSING BELIEFS, ATTITUDES AND KNOWLEDGE OF  
                        DOCTORS REGARDING HIV PrEP 
Demographic information 
________________________________________________________ 
2.       Which province and suburb in South Africa do you currently practise in? 
 
 
3. Do you identify as: 









7.         If other, please specify: 
 
4. What type of  doctor are you? 
Mark only one option 
 General practitioner/family physician 
 Infectious disease specialist 
 General internist 
 Other 
6. In what type of setting do you practise predominantly? 
Mark only one option 
 Private practice 
 Community hospital 
 Academic hospital 
 Community health centre 
 Walk-in clinic 
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8.        What percent of your work time do you spend on clinical activities? 
__________________________________________________________________________________ 
9.        What percent of your work time do you spend on administrative activities? 
__________________________________________________________________________________ 
 
10.      What percent of your work time do you spend on research activities? 
_________________________________________________________________________________ 
11.       What percent of your work time do you spend on Public Health? 
_________________________________________________________________________________ 




14.         How many years have you been an independent practitioner? 
__________________________________________________________________________________ 
15.         What proportion of your patient population is HIV positive (please enter an estimated 
                percentage)? 
__________________________________________________________________________________ 
16.         What proportion of your patient population is HIV negative but at high risk of HIV  
               acquisition (please enter an estimated percentage)? 
 
13. I identify as a specialist in HIV care. 
 Mark only one option 




 Strongly agree 
17. Does your practice serve a substantial population of any of the following groups. 
  check all that apply 
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Questions about  HIV PrEP 
Pre-exposure prophylaxis for HIV prevention 
 
PrEP is a new HIV prevention method that has recently been found effective in clinical trials. Truvada 
has also been approved for use as PrEP on 08 December 2015 by the Medicines Control Council of 
South Africa.  It involves an HIV-negative individual taking anti-retroviral drugs in an effort to reduce 
their risk of becoming infected with HIV. Using the current strategy, PrEP drugs (typically 
tenofovir/emtricitabine (Truvada) and/or tenofovir on its own) need to be taken daily on a regular 
basis —starting before and continuing after exposure to HIV. 
Clinical trials show that PrEP is only partially protective against HIV infection and much less so if not 
taken consistently. People using PrEP would need to commit to regular doctor’s appointments to 
monitor adverse effects and adherence. Patients would also require regular testing for HIV and other 
sexually transmitted infections.  
In this survey, PrEP specifically refers to the daily use of anti-retroviral pills by people who are HIV-
negative, also known as oral PrEP. PrEP is not the same as post-exposure prophylaxis or PEP, which is 
the daily use of antiretroviral pills for 28 days AFTER a potential exposure. 
__________________________________________________________________________________ 
             
 Gay, bisexual and other men who have sex with men 
 Transgender individuals 
 People who use injection drugs 
 Prison inmates 
 Sex workers and their clients 
 Women 
18. How would you describe your current knowledge of HIV pre-exposure prophylaxis? 
  Mark only one option 
 Not familiar at all    (first time I hear about it)                                               Skip to question 31. 
 Somewhat familiar (I am aware of PrEP and the existence of clinical trials but not of their 
details)                                                                                                                 Skip to question 19. 
 Very familiar            (I am aware of the details of recent clinical trials)    Skip to question 19. 
19. Where did you hear about PrEP? 
  check all that apply 
 Peer-reviewed medical journal 
 HIV/AIDS-related or other medical conference 
 Workshop, lecture or seminar 
 Colleagues 
 Client/patient 
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21.          Do you have any thoughts/opinions/concerns on the use of oral PrEP for the prevention 











26.        If you answered yes to the previous question, how many times have you prescribed PrEP 
 Website or blog 
 Other 
22. Have you ever been questioned by a patient about pre-exposure prophylaxis (PrEP)? 
  Mark only one option 
 Yes 
 No 
23. Who has asked you about PrEP? 
  check all that apply 
 Men who have sex with men 
 People in serodiscordant relationships 
 Person/s working as commercial sex workers 
 Person/s using intravenous drugs 
 Other 
25. Have you ever prescribed PrEP as an HIV prevention option to a patient? 
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  in the last year? 
__________________________________________________________________________________ 
28. If other, please specify:
Opinions about PrEP 
__________________________________________________________________________________ 
27. To whom have you prescribed PrEP?
check all that apply
Men who have sex with men
People in serodiscordant relationships
Person working as a commercial sex worker
Person using intravenous drugs
Other
29. If you have spoken to a patient about PrEP, were you generally:




30. If any of your patients obtained PrEP off-label, do you know how they obtained it?
check all that apply
Off-label prescription by a doctor
Internet purchase
From an HIV positive partner or friend
Other informal channels (eg obtained on the street)
Unsure
Llewellyn Fleurs (FLRLLE001) 






  32. To what extent do you agree with the following statements: 
 Mark only one option per row 
 Strongly 
disagree 
Disagree Neutral Agree Strongly agree 
PrEP is 
dangerous and 
should not be 
pursued 
further 
     
PrEP is a 
useless 
distraction 
     
PrEP may be 
useful but is 
not ready to 
be made more 
widely 
available 
     










     
 
33.                         What is the MINIMUM level of protection you would consider reasonable for  
                                PrEP use to be recommended to individuals at high risk of HIV infection? 
                                Please report a percentage value. For example, “x”= x % reduction in HIV  
                                Infection. 
31. Knowing what you know about PrEP now, would you prescribe PrEP for a patient at high 
risk of infection? 
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36.         In the context of the previous question, how would you define a large number of sexual 
               partners? (please enter minimum number of partners per month) 






34. PrEP will likely be recommended to individuals at high risk for HIV infection. How would 
you define high risk in this context? 
  check all that apply 
 Gay, bisexual or other men who have sex with men 
 Individuals with a large number of sexual partners 
 Individuals with a history of one or more STIs 
 Individuals who have sex under the influence of drugs 
 Individuals who have used post-exposure prophylaxis (PEP) before (ie have taken 
antiretroviral drugs AFTER exposure to HIV to prevent becoming infected) 
 People who use injection drugs and other people who may share needles 
 HIV negative individuals who are sexually active with HIV positive partners on an ongoing 
basis 
 Individuals who exchange sex for money, goods or housing 
 Individuals who belong to any population with a high incidence of HIV 
 Other 
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37.         In the context of the previous question, how would you define regularly engaging in  
               unprotected sex? (please enter minimum number of unprotected sexual encounters 










40.         If other, please specify: 
 
 
38. According to one study among men who have sex with men (MSM), oral PrEP provided 
44% protection against HIV infection overall and 73% protection in participants who used 
PrEP consistently (ie took the medication on a regular schedule and did not miss any 
doses). Other studies show similar levels of protection in heterosexual men and women. 
Considering this level of protection, do you believe the Medicines Control Council was right 
to approve PrEP for use in South Africa? 




39. Who do you think should pay for PrEP in South Africa? 
  check all that apply 
 Public drug plans ( the government) 
 Private drug plans 
 The taxpayer through eg a National Health Insurance 
 The patient using PrEP 
 Other 
41. In what kind of settings do you think PrEP should be prescribed? 
  check all that apply 
 Dedicated PrEP clinics 
 Incorporated into STI or HIV clinics 
 Individual doctor’s offices (like any other health issue) 
 Other 
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42.         If other, please specify: 
 
  43. The following issues have been raised as important considerations for the 
implementation of oral PrEP. To what extent do each of these issues shape your 
beliefs and opinions about whether or not PrEP should be made widely available 
in South Africa? 
 Mark only one option  per row 








Efficacy (ie the 
% decrease in 
risk of HIV 
infection) 













     







     
Risk that 
patients may 






     
Risk that 
patients may 





     
Cost-      
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44. Please rank the THREE considerations you believe are the MOST IMPORTANT in
order from LEAST to MOST important.
Mark only one option per row
Most important Second most important Third most important 
Efficacy (ie the 
% decrease in 
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45.                        Do you have any other concerns that were not mentioned that you feel are 







  46. After considering the issues above, to what extent do you agree with the 
following statements? 
 Mark only one option per row 
 strongly 
disagree 
disagree neutral agree strongly agree 
Policy makers 
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efforts 
Investing in 













48. To what extent do you agree with the following statements?
Mark only one option per row
strongly 
disagree
disagree neutral agree strongly agree 
I have enough 
knowledge of 




I think that 
information 






47. Do you think some of the patients you serve would benefit from PrEP?




49. The following media would be useful to me in learning more about PrEP:
check all that apply
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55.         What do you think is needed, in general, before PrEP is made more widely available as an  
 Access to papers from peer-reviewed journals 
 Website 
 CPD event or workshop 
 Online learning modules 
 Brochure 
 N/A ( I do not need more information about PrEP) 
 Other 
51. What are the current barriers against prescribing PrEP? 
  check all that apply 
 I am not familiar enough with PrEP to prescribe it 
 I am unsure of which patients to prescribe it to 
 I do not think my patients would be interested in PrEP as an option 
 My patients are unable to get the drug costs covered 
 I do not feel there is sufficient data to support its use 
 Other 
53. What supports would your practice need before implementing PrEP? 
  check all that apply 
 Adherence counselling by trained counsellor 
 Continuing medical education on new evidence for PrEP 
 Nursing support for ongoing patient counselling, routine STI and HIV testing and monitoring 
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Thank you very much for taking the time to fill out this survey. 
After pressing the “done”  button below responses will be saved and you will no longer have the 
option to withdraw from the study. 
A copy of the consent form can be downloaded for your records by clicking on the following link: 
https://drive.google.com/file/d/0B-MXAuKr2aLOZVBCSFFvaDBXV28/view?usp=sharing 
If you would like to download the 2016 South African guidelines on the use of Truvada as PrEP, you 
can do so by clicking on the following link: 
https://drive.google.com/open?id=0B-MXAuKr2aLOTHBtMlE0ZGp4V28 
To enter the draw to win an Ipad, you may email Dr Llewellyn Fleurs by clicking on the link below: 
llewiwanttheipad@gmail.com 
Please send your name, surname, suburb and province you practise in, and a contact number in the 
email. 
If there are any questions you may contact the Principal Investigator Professor Linda-Gail Bekker at 
linda-gail.bekker@hiv-research.org.za or (021) 406 6970 or Dr Llewellyn Fleurs at 






Llewellyn Fleurs (FLRLLE001) 







APPENDIX 5: BUDGET FOR PROJECT 
   BUDGET FOR DISSERTATION PROJECT (FLRLLE001) 
   ITEM QUANTITY PRICE 
Creating online survey 1 4188.00 
Sending out emails to doctors 14325 0.00 
Ipad for competition 1 13999.00 
      
TOTAL   18187.00 
      
      
   NOTES: 
  
   Study will be conducted using no official funding. 
The Ipad will be bought through the Desmond Tutu 
Research Foundation. 
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be used, and they should be spelt out at first use followed by the abbreviation in brackets. SI 
units should be used, with litre and molar being permitted. 
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In the cover letter, please explain why your manuscript should be published in the journal. If 
necessary, address any issues relating to our editorial policies (see About JIAS) and declare 
any competing interests (see Competing interest).  
 
You can also suggest potential peer reviewers for your manuscript: they should be experts in 
the field and be able to provide an objective assessment of the manuscript. Any suggested 
peer reviewers should not have published with any of the authors of the manuscript within the 
past five years, should not be current collaborators, and should not be members of the same 
institution. Suggested reviewers will be considered alongside potential reviewers identified 
by the Editorial team. 
 
Members of the International AIDS Society receive a 15% discount on the publication fee. 
Authors should include their valid membership number in the cover letter upon submission.  
 
Title page 
On the title page, you should mention the title of the manuscript, list all authors' names in 
full, and list any study groups if applicable. Each authors' affiliation should be numbered in 
superscript consecutively and listed underneath, including department, institution, city and 
country. The corresponding author should be marked with the symbol § in superscript and 
full contact details should be provided, including a telephone number with country code. 
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Abstract 
The Abstract should not exceed 350 words and should be structured according to the 
headings of the selected article category (see below), excluding the heading, Discussion for 
Research articles. Avoid using abbreviations and do not cite references in the Abstract. If you 
are reporting results from a controlled health care intervention, please include your trial 
registry, together with your unique identifying number at the end of the Abstract. For 
randomized controlled trials, follow the CONSORT extension for abstracts.  
 
Main text 
More information on the different article categories is provided below, including specific 
section headings and word limits. Information on the different sections in the manuscript is 
further detailed below, as well.  
 
Article categories 
Research - full reports of data from original research studies 
Headings: Introduction, Methods, Results, Discussion, Conclusions 
Word limit: 3500 words 
Numbers of figures and tables: Unlimited 
Additional files: Yes 
Llewellyn Fleurs (FLRLLE001) 
Masters of Public Health (MPH) thesis Page 44 
 
Manuscript template  
 
Short report - brief reports of data from original research, such as follow-up or confirmatory 
studies, case series and negative results 
Headings: Introduction, Methods, Results and discussion, Conclusions 
Word limit: 2500 words 
Numbers of figures and tables: 4 
Additional files: No 
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Review - comprehensive, authoritative descriptions and summaries of a specific subject area 
providing a systematic and substantial overview of the field  
Headings: Introduction, Methods (if applicable), Results and discussion (if applicable, 
otherwise Discussion only), Conclusions 
Word limit: 5000 words 
Numbers of figures and tables: Unlimited 
Additional files: Yes 
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Debate - presentation of an evidence-based argument 
Headings: Introduction, Discussion, Conclusions 
Word limit: 3500 words 
Numbers of figures and tables: 4 
Additional files: No 
Manuscript template  
 
Commentary - focused and opinionated articles on important and timely issues 
Headings: Introduction, Discussion, Conclusions 
Word limit: 2500 words 
Numbers of figures and tables: 1 
Additional files: No 
Manuscript template  
 
Letter to the Editor - comments on and responses to published articles  
Headings: None 
Word limit: 500 words 
Numbers of figures and tables: None 
Additional files: No 
Manuscript template  
Viewpoint - constructive, stand-alone views on current topics 
Headings: None 
Word limit: 1000 words 
Numbers of figures and tables: 1 
Additional files: No 
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The Introduction section should introduce the topic to readers without specialist knowledge in 
that area and must clearly outline the current state of knowledge in this field, the motivation 
and the aim of the study or the article.  
 
Methods 
The Methods section should include all information necessary to repeat the study, in 
particular, the study design, how data was collected and analyzed, clarifying the choice of 
methods that were made. If applicable, you should describe the setting of the study, the dates 
the study were conducted, and the sample or participants, as well as necessary power 
calculations and materials, including statistical packages, used. Interventions and 
programmes should be described in detail. Generic names for drugs or any molecules should 
be used.  
 
All studies involving humans or animals require a statement on ethical approval, and for the 
former, the consent procedure that was followed. Please include the names of the ethics 
review board(s) that approved the study. If the research study was specific to one sex/gender, 
the reasons for this should be clearly stated.  
 
Results 
This section should include only data and findings from the authors' study. Presentation of 
statistical results should mention confidence intervals and levels of significance where 
appropriate. Quotes from qualitative study participants of less than three lines should be 
quoted in the text using quotation marks. For quotes longer than three lines, place the quote in 
a separate, indented paragraph and introduce it with a colon. No quotation marks are needed 
in this case. Details of the participant can be added in round brackets following the quote, but 
should not contain identifiable information to ensure confidentiality. Clarifications within the 
quotation should be placed in square brackets.  
 
Submitting authors are strongly encouraged to include data disaggregated by sex (and, 
whenever possible, by race) and provide a comprehensive analysis of gender and racial 
differences. The authors should include the number and percentage of men, women and, if 
appropriate, transgender persons who participated in the research study. Anatomical and 
physiological differences between men and women (height, weight, body fat-to-muscle 
ratios, cell counts, hormonal cycles, etc.), as well as social and cultural variables (socio-
economic, education, access to care, etc.), should be taken into consideration in the 
presentation of data and/or analysis of the results.  
 
Discussion 
In the Discussion section, you should discuss your main findings and place these within the 
context of the current body of knowledge in the field. Limitations of the study, for example, 
selection bias, can also be discussed, and should address how these influence the results and 
conclusions. If statistically significant differences were found between men and women or 
between different racial or cultural groups in the effects of the studied intervention, the 
implications, if any, for clinical and/or public health should be adequately discussed. 
 
Conclusions 
In your Conclusions section, state your key messages from the study and explain their 
importance and relevance, as well as implications. Future studies and recommendations can 
be included in this section. The conclusions drawn must be strictly based on the data 
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Figures should be integrated into the text at the appropriate place. Figures should be cropped 
as closely as possible and have the header: "Figure 1. Title of figure". All figures need to be 
cited in the text in consecutive order. Legends should be provided underneath the figures, 
listing any abbreviations or meanings of symbols used. If several figures are included, please 
ensure that symbols are used consistently. Sufficient information needs to be provided for the 
figure to stand alone, including labels of axes. Please ensure that figures are legible in black 
and white print and also compatible with colour blindness. If figures are copied or adapted 
from another source, authors must seek permission prior to publication and these should be 
clearly cited as such. If the complete figure spans more than one page, authors should upload 
the figure as an additional file instead. High-resolution illustrations are recommended for 
optimal viewing performance in the final article.  
 
Tables 
Tables must be created within the word file in the correct place and should have the header: 
"Table 1. Title of table". All tables should be cited in the text in consecutive order. The tables 
should not contain colour or shading, and no vertical, visible lines. A legend can be provided 
underneath the title, listing any abbreviations or meanings of symbols used. If several tables 
are included, please ensure that symbols are used consistently. If tables are copied or adapted 
from another source, permission must be sought by the authors prior to publication and these 
should be clearly cited as such. If a table spans more than one page, authors may want to 
consider uploading the table as an additional file instead.  
 
References 
All external sources of information should be referenced within the text, the tables and 
figures, using consecutive numbering in square brackets, e.g. [1], [3-5], [3,4]. The references 
should be up to date and adequately reflect the current state of knowledge in the field. 
Citation bias, for example, by country or point of view must be avoided. Numbers of 
references are unlimited for all article categories and should be formatted in standard 
Vancouver style; see Sample references from ICMJE. Unpublished observations, personal 
communications and manuscripts currently under consideration should be cited in the text in 
round brackets and not in the reference list.  
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Table 4: Summary of model building 
 
MODEL LOG LIKELIHOOD  LR TEST  AIC 
  chi^2 p value compared 
to 
 
A.    Constant -21.61 0 N/A  N/A 
 
Adding potential confounders 
B.    Years of experience (10 year  
        Increments) 
-21.55 0.14 0.71 Constant N/A 
        Female sex -21.57 0.1 0.76 constant N/A 
        Self-identified specialist in 
        HIV care 
-21.57 0.08 0.77 constant N/A 
        Infectious disease specialist -20.86 1.5 0.22 Constant N/A 
        Academic setting -20.52 2.2 0.14 Constant N/A 
        Private practice .Perfect                
success* 
    
        Time spent in clinical work 
         (10% increments) 
-20.80 1.62 0.20 Constant N/A 
        Time spent in administrative 
         work (10% increments) 
-21.59 0.04 0.84 Constant N/A 
        Time spent in research 
         (10% increments) 
-19.53 4.16 0.04 Constant N/A 
         Time spent in public health 
          (10% increments) 
-21.61 0.01 0.92 Constant N/A 
         Time spent in teaching 
         (10% increments) 
-19.25 4.73 0.03 Constant N/A 
        HIV positive patients 
        (10% increments) 
-21.38 0.46 0.49 Constant N/A 
        High risk HIV negative 
       patients (10% increments) 
-21.52 0.19 0.66 Constant N/A 
       High percentage of MSM 
       patients 
-21.09 1.05 0.30 Constant N/A 
       High percentage of  
       transgender patients  
Perfect success*     
      High percentage of patients 
      who inject drugs   
Perfect success*     
      Prison inmates as patients -21.53 0.17 0.68 Constant N/A 
      Sex workers as patients Perfect success*     
      Female patients 
      (serodiscordant partners)    
Perfect success*     
      Previous knowledge of HIV -21.48 0.28 0.60 Constant N/A 
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 PrEP 
 Knowledge of PrEP from  
 journals 
-20.51 2.20 0.14 Constant N/A 
 Knowledge of PrEP from 
 conferences 
-21.07 1.08 0.30 Constant N/A 
 Knowledge of PrEP from 
 seminars 
-20.64 1.94 0.16 Constant N/A 
 Knowledge of PrEP from  
 discussion  with colleagues 
-21.58 0.07 0.79 Constant N/A 
 Knowledge of PrEP from 
 patients 
Perfect success* 
 Knowledge of PrEP from  
 websites 
-21.27 0.70 0.40 Constant N/A 
 Other sources of knowledge 
 about PrEP 
Perfect success* 
     Being asked about PrEP from 
     Any patient 
-20.33 2.56 0.11 Constant N/A 
    Efficacy rated as most  
    important 
-20.75 1.73 0.19 Constant N/A 
    Development of HIV resistance 
    rated as most important 
-21.60 0.01 0.90 Constant N/A 
    Development of side effects 
    rated as most important 
Perfect success* 
    Patient disinhibition rated 
    as most important 
-21.44 0.35 0.55 Constant N/A 
    Clinical monitoring of patients 
    rated as most important 
-21.60 0.03 0.87 Constant N/A 
    Patient compliance rated as 
    most important 
-21.38 0.47 0.49 Constant N/A 
    Cost-effectiveness rated as  
    most important 
-20.34 2.54 0.11 Constant N/A 
    Patient access to Truvada  
    rated as most important 
-21.34 0.54 0.46 Constant N/A 
    Adherence counselling=  
    facilitating factor 
-21.55 0.13 0.72 Constant N/A 
    Continuing medical education= 
    facilitating factor 
-21.32 0.59 0.44 Constant N/A 
    Nursing support= 
     facilitating factor 
-21.18 0.87 0.35 Constant N/A 
     Other facilitating factors -21.46 0.32 0.57 Constant N/A 
Adding potential risk factors 
C. Time spent in teaching+
time spent in research
-17.92 2.65 0.10 Time spent 
in teaching 
41.84 
*omitted from model
__________________________________________________________________________________ 
